(Q46071397)

English

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

M C Genovese

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

N Kinnman

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

G de La Bourdonnaye

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

C Pena Rossi

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

P P Tak

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

63

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

1793-1803

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Treatment of rheumatoid arthritis: state of the art 2009.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

B cells in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

An APRIL to remember: novel TNF ligands as therapeutic targets

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

BAFF mediates survival of peripheral immature B lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Synovial tissues concentrate secreted APRIL.

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Intestinal Bacteria Trigger T Cell-Independent Immunoglobulin A2 Class Switching by Inducing Epithelial-Cell Secretion of the Cytokine APRIL

1 reference

https://api.crossref.org/works/10.1002%2FART.30373

21 January 2018

Identifiers

10.1002/ART.30373

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/21452293

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46071397&oldid=2090635607"